Improving the rigor and utility of botanical toxicity studies: Recommended resources.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 15 05 2023
revised: 04 08 2023
accepted: 17 08 2023
pmc-release: 01 10 2024
medline: 11 10 2023
pubmed: 22 8 2023
entrez: 21 8 2023
Statut: ppublish

Résumé

Interest in botanicals, particularly as dietary supplement ingredients, is growing steadily. This growth, and the marketing of new ingredients and combination products as botanical dietary supplements, underscores the public health need for a better understanding of potential toxicities associated with use of these products. This article and accompanying template outline the resources to collect literature and relevant information to support the design of botanical toxicity studies. These resources provide critical information related to botanical identification, characterization, pre-clinical and clinical data, including adverse effects and interactions with pharmaceuticals. Toxicologists using these resources should collaborate with pharmacognosists and/or analytical chemists to enhance knowledge of the botanical material being tested. Overall, this guide and resource list is meant to help locate relevant information that can be leveraged to inform on decisions related to toxicity testing of botanicals, including the design of higher quality toxicological studies.

Identifiants

pubmed: 37604297
pii: S0273-2300(23)00139-3
doi: 10.1016/j.yrtph.2023.105471
pmc: PMC10591999
mid: NIHMS1929006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105471

Subventions

Organisme : Intramural NIH HHS
ID : ZIA ES103316
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA ES103373
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Clin Pharmacol Ther. 2018 Sep;104(3):435-445
pubmed: 29947417
Ann Intern Med. 2006 Mar 7;144(5):364-7
pubmed: 16520478
Toxicol Rep. 2020 Feb 15;7:386-402
pubmed: 32140423
Forsch Komplementarmed Klass Naturheilkd. 2003 Apr;10 Suppl 1:9-12
pubmed: 12808356
Front Pharmacol. 2022 Sep 30;13:981978
pubmed: 36249773
Fed Regist. 2004 Feb 11;69(28):6787-854
pubmed: 14968803
Clin Pharmacol Ther. 2010 Feb;87(2):149-51
pubmed: 20107447
Planta Med. 2012 Sep;78(13):1478-89
pubmed: 22322396
Front Nutr. 2021 Dec 14;8:786261
pubmed: 34970578
FASEB J. 2020 Jan;34(1):41-65
pubmed: 31914647
JAMA. 2022 Dec 13;328(22):2252-2264
pubmed: 36511921
Br J Clin Pharmacol. 2015 Apr;79(4):578-92
pubmed: 25251944
Phytomedicine. 2018 Jun 1;45:105-119
pubmed: 29778318
J Food Drug Anal. 2018 Apr;26(2S):S12-S25
pubmed: 29703380
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
Regul Toxicol Pharmacol. 2022 Feb;128:105090
pubmed: 34863907
Br J Pharmacol. 2020 Mar;177(6):1212-1226
pubmed: 31742659
Drug Alcohol Depend. 2021 Jan 1;218:108426
pubmed: 33257199
Regul Toxicol Pharmacol. 2017 Oct;89:50-56
pubmed: 28689746
J Toxicol. 2013;2013:802453
pubmed: 23554812
Nat Prod Rep. 2019 Aug 14;36(8):1196-1221
pubmed: 30681109
J Multidiscip Healthc. 2016 May 04;9:211-7
pubmed: 27217764
Regul Toxicol Pharmacol. 2020 Jun;113:104642
pubmed: 32197968
Clin Pharmacol Ther. 2018 Sep;104(3):426-429
pubmed: 30066384
J Nutr. 2018 Aug;148(Suppl 2):1428S-1435S
pubmed: 31249427
Ann Intern Med. 2017 Jun 27;167(2):112-121
pubmed: 28654980

Auteurs

Deval Patel (D)

Amway Corporation, Buena Park, California, USA.

Barbara C Sorkin (BC)

Office of Dietary Supplements, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, USA.

Constance A Mitchell (CA)

Health and Environmental Sciences Institute, Washington, DC, USA. Electronic address: cmitchell@hesiglobal.org.

Michelle R Embry (MR)

Health and Environmental Sciences Institute, Washington, DC, USA.

Sharline Rina-Kong (S)

Amway Corporation, Buena Park, California, USA.

Rebecca E Adams (RE)

NSF International, Ann Arbor, MI, USA.

Emily R DeTemple (ER)

Indiana University, Bloomington, IN, 47405, USA.

Aalekhya Reddam (A)

Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.

Stefan Gafner (S)

American Botanical Council, Austin, TX, USA.

Olaf Kelber (O)

Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany.

Cynthia V Rider (CV)

Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

Hellen Oketch-Rabah (H)

United States Pharmacopeial Convention (USP), Rockville, MD, USA.

Amy L Roe (AL)

Procter & Gamble Company, 8700 Mason-Montgomery Rd, Box 2006, Cincinnati, OH, 45040, USA.

Robin J Marles (RJ)

USP Botanical Dietary Supplements and Herbal Medicines Expert Committee, United States Pharmacopeial Convention (USP), Rockville, MD, USA.

Joseph Dever (J)

Amway Corporation, Buena Park, California, USA; NSF International, Ann Arbor, MI, USA.

Steven Dentali (S)

Dentali Botanical Sciences, Redondo Beach, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH